Tanglewood Legacy Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Tanglewood Legacy Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.4K	Hold	25	–	–	﹤0.01%	227
2026 Q1	$11.2K	Hold	25	–	–	﹤0.01%	223
2025 Q4	$11.3K	Hold	25	–	–	﹤0.01%	219
2025 Q3	$9.79K	Hold	25	–	–	﹤0.01%	234
2025 Q2	$11.1K	Hold	25	–	–	﹤0.01%	241
2025 Q1	$12.1K	Hold	25	–	–	0.01%	242
2024 Q4	$10.1K	Hold	25	–	–	﹤0.01%	251
2024 Q3	$11.6K	Hold	25	–	–	0.01%	231
2024 Q2	$11.7K	Hold	25	–	–	0.01%	232
2024 Q1	$10.4K	Hold	25	–	–	0.01%	247
2023 Q4	$10.2K	Hold	25	–	–	0.01%	242
2023 Q3	$8.69K	Hold	25	–	–	0.01%	253
2023 Q2	$8.8K	Hold	25	–	–	0.01%	249
2023 Q1	$7.88K	Hold	25	–	–	0.01%	247
2022 Q4	$7.22K	Buy	+25	New	+$7.62K	0.01%	216

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tanglewood Legacy Advisors's VRTX Position: Q2 2026 in Review

Tanglewood Legacy Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 25 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #227.

Tanglewood Legacy Advisors first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Tanglewood Legacy Advisors held 25 shares of Vertex Pharmaceuticals worth $12.4K as of Q2 2026.
Tanglewood Legacy Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Tanglewood Legacy Advisors's portfolio in Q2 2026, its #227 holding.
Tanglewood Legacy Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tanglewood Legacy Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.